Efficacy of surgery after successful chemotherapy for advanced gastric cancer

被引：2

作者：

Seike K. ^{[1
,7
]}

Ohtsu A. ^{[2
]}

Yoshida S. ^{[2
]}

Kinoshita T. ^{[1
]}

Ono M. ^{[1
]}

Koizumi W. ^{[3
]}

Miyata Y. ^{[4
]}

Shirao K. ^{[5
]}

Shimada Y. ^{[5
]}

Kurihara M. ^{[6
]}

机构：

[1] Department of Surgery, National Cancer Center Hospital East, Kashiwa

[2] Department of Internal Medicine, National Cancer Center Hospital East, Kashiwa

[3] Department of Internal Medicine, Kitasato University East Hospital, Sagamihara

[4] Department of Internal Medicine, Saku Central Hospital, Nagano

[5] Department of Internal Medicine, National Cancer Center Hospital, Tokyo

[6] Department of Gastroenterology, Toyosu Hospital, Showa University, Tokyo

[7] First Department of Surgery, Chiba University, Chuo-ku, Chiba 260-0856

来源：

International Journal of Clinical Oncology | 1998年 / 3卷 / 3期

关键词：

Chemotherapy; Combined modality; Gastric cancer; Surgery;

D O I：

10.1007/BF02489909

中图分类号：

学科分类号：

摘要：

Background: We evaluated the efficacy of surgical resection after successful chemotherapies in patients with advanced gastric cancer. Methods: Eighteen surgical patients who had had successful chemotherapies were selected after a review of 218 case records. Results: The 18 patients were grouped by their pretreatment status: 8 patients with distant lymph node metastases (N4 group), 7 with a small amount of ascites (P group), and 3 with both factors (N4 + P group). Good responses were achieved in all of the 11 patients with node metastases, including 4 patients with a complete response. Ascites in 7 of 10 patients disappeared. Two of 18 patients (11%) achieved curability A resections, while 8 patients (44%) achieved curability B and 8 (44%) achieved curability C resections. Pathologic complete responses were documented in 2 patients of the N4 group. The median survival time of the 18 patients was 14 months, with a 1-year survival rate of 61%. Six patients have survived more than 2 years, and 3 more than 5 years to date. The 8 N4-group patients who had surgery showed significantly better survival than 19 similar patients who had distant metastases and responded to chemotherapy but did not have surgery. A similar comparison of the P-group patients found no significant difference in survival associated with surgery. Conclusions: Surgery after chemotherapy might be beneficial for patients with distant lymph node metastases, but not effective for those with peritoneal dissemination.

引用

页码：159 / 164

页数：5

共 17 条

[1] Maryuyama K., Sasako M., Kinoshita T., Sano T., Katai H., Surgical treatment for gastric cancer: The Japanese approach, Seminars in Oncology, 23, pp. 360-368, (1996)
[2] Ogawa M., A current overview of chemotherpy in advanced gastric cancer, J Jpn Soc Cancer Ther, 16, pp. 2161-2168, (1989)
[3] Suzuki H., Nunomura M., Sarashina H., Saitoh N., Koda K., Takiguchi N., Oda K., Takeuchi O., Shindoh H., Hanagasaki K., Kondoh K., Soda H., Terado T., Ozaki K., Sugaya Y., Ezawa E., Kondoh E., Wakatsuki K., Chiku T., Nakajima N., A case of Borrmann 3 type gastric cancer with remarkably effective preoperative chemotherapy, J Jpn Soc Clin Surg, 55, pp. 2315-2319, (1994)
[4] Takemoto T., Karasawa Y., Kurihara M., A remarkably effective case of advanced gastric cancer treated by combination of 5-DFUR and CDDP, J Jpn Soc Cancer Ther, 31, pp. 1136-1141, (1996)
[5] Imai S., Shibuya T., Uchiyama K., Suzuki S., Takahashi N., Miyairi K., Kokuma M., Sakamoto T., Suzuki S., Kato H., A case report of unresectable gastric cancer having a long term partial response and finally undergoing radical operation following FAM therapy and administration of 5-DFUR, J Jpn Soc Clin Surg, 57, pp. 597-603, (1996)
[6] Urabe T., Akazawa S., Suda Y., Minaguchi S., Yoshida S., Clinical application of sequential dose MTX and 5-FU as a neoadjuvant chemotherapy for advanced stomach carcinoma, J Jpn Soc Cancer Ther, 21, pp. 2284-2295, (1996)
[7] Suzuki T., Kashiwabara H., Hachisu T., Oompri K., Sakamoto K., Amano H., Yokoyama T., A remarkable effect of pre-operative cancer therapy in a case of Borrmann 4 type gastric cancer with massive ascites, Jpn J Gastroenterol Surg, 24, pp. 3000-3003, (1991)
[8] Tsuneda Y., Fujii M., Ishii Y., Itoh Y., Kochi M., Takano S., Masuda H., Imai S., A case of advanced gastric cancer successfully treated with curative resection after FLEP (5-FU, leucovorin, etoposide, CDDP) combined chemotherapy, J Jpn Soc Cancer Ther, 31, pp. 456-462, (1996)
[9] Hoshino K., Nakamura M., Kamoshita N., Ikeda H., Kobayashi J., Tanaka T., Koyama T., Morishita Y., Unresectable gastric cancer followed by remarkably effective tumor disappearance and good quality of life for 10 months after CDDP/5-DFUR combination chemotherapy - A case report, Jpn J Cancer Chemother, 23, pp. 1841-1845, (1996)
[10] Preusser P., Wilke H., Achterrath W., Fink U., Lenaz L., Heinicke A., Meyer J., Meyer H.J., Buente H., Phase II study with the combination etoposide, adriamycin and cisplatin in advanced measurable gastric cancer, J Clin Oncol, 7, pp. 1310-1317, (1989)

← 1 2 →